Abstract
Many chemotherapy regimens are used for treating SCLC in the United Kingdom, but it is not known, in any detail, which regimens are used, by which specialists, for which types of patient. We conducted a survey among all medical and clinical oncologists, respiratory physicians and general physicians with respiratory interest in the United Kingdom to find out. The questionnaire asked for the number of SCLC patients treated annually; how many were given chemotherapy; the drugs, doses and schedules chosen according to prognostic group (as defined by the clinician); and the reasons for choice of regimen. 1214 questionnaires were sent out, and responses were received from 1070 (88%) clinicians; 266 (25%) of these treated SCLC with chemotherapy. Of 4674 patients given chemotherapy annually, 36% were given it by clinical oncologists, 30% by medical oncologists, 27% by respiratory physicians, and 7% by general physicians. In all, 34 regimens were reported with 151 different combinations of dose and schedule. In 2311 good prognosis patients, 23 regimens were used, the commonest being ACE (doxorubicin, cyclophosphamide, etoposide), ICbE (ifosfamide, carboplatin, etoposide), CAV (cyclophosphamide, doxorubicin, vincristine), CbE (carboplatin, etoposide), and PE (cisplatin, etoposide). In 1517 poor prognosis patients, 21 regimens were used, the commonest being CAV, EV (etoposide, vincristine), CbE, CAV alternating with PE, and oral etoposide. 452 patients were treated regardless of prognosis and for 219 no prognostic criteria were specified. The remaining 175 were given second-line chemotherapy or were given regimens chosen to avoid toxicity or because of intercurrent disease or other reasons. The main reasons affecting choice of regimen were routine local practice, patients' convenience, quality of life considerations, trial results and cost. The results show wide variation in routine practice and will be useful in reporting and planning clinical trials and in deciding on local treatment policies. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arriagada R, Le Chevalier T, Pignon J-P, Rivière A, Monnet I, Chomy P, Tuchais C, Tarayre M and Ruffié P (1993) Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329: 1848–1852
Carney DN and Shepherd FA (2000) Treatment of SCLC: Chemotherapy. In: Textbook of Lung Cancer, Hansen HH (ed) pp 261–272. Martin Dunitz: London
Cerny T, Blair V, Anderson H, Bramwell V and Thatcher N (1987) Pretreatment prognostic factors and scoring system in 407 small cell lung cancer patients. Int J Cancer 39: 146–149
Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, Ward M, Richards M, Stableforth D, MacFarlane J, Fletcher J and David D and the Midlands Small Cell Lung Cancer Group (1986) Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol 17: 157–160
Ettinger DS (1995) New drugs for treating small cell lung cancer. Lung Cancer 12 (supplement 3): S53–S61
Giaconne G, Delasio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JTM, Bakker W, Koolen MGJ, Venrik CPJ, Roozendaal KJ, Planting AST, van Zandwijk N, ten Velde GJM and Splinter TAW, for the European Organization for Research Treatment of Cancer Lung Cancer Cooperative Group (1993) Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 11: 1230–1240
Groen HJM, Fokkema E, Biesma B, Kwa B, Putte NJWG VAN, Postmus PE and Smit EF (1999) Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol 17: 927–932
Johnson DH (1993) Treatment of limited-stage small cell lung cancer: recent progress and future directions. Lung Cancer 9 (supplement 1): S1–S19
Medical Research Council Lung Cancer Working Party (1989) Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 59: 584–590
Medical Research Council Lung Cancer Working Party (1993) A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: survival and prognostic factors. Br J Cancer 68: 1150–1156
Medical Research Council Lung Cancer Working Party (1996) Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Lancet 348: 563–566
Murray N (1997) Treatment of small cell lung cancer: the state of the art. Lung Cancer 17 (supplement 1): S75–S90
NHS Executive (1998) Guidance on Commissioning Cancer Services; Improving Outcomes in Lung Cancer, The Research Evidence, Department of Health: London
Pujol J-L, Carestia, Daurès J-P (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83: 8–15
Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, Lamont A and Harper PG (1997) Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89: 577–580
Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, Tobias JS, Partridge M and Eraut D (1989) Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 59: 578–583
Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W and Stephens RJ, for the Medical Research Council Lung Cancer Working Party (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicentre randomized trial. J Clin Oncol 18: 395–404
Turrisi AT, III, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S and Johnson DH (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265–271
World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. WHO: Geneva
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sambrook, R., Girling, D. A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. Br J Cancer 84, 1447–1452 (2001). https://doi.org/10.1054/bjoc.2001.1817
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1817
Keywords
This article is cited by
-
Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group
Medical Oncology (2012)
-
A population-based study of gefitinib in patients with non-small cell lung cancer
Medical Oncology (2009)
-
The impact of cancer research: how publications influence UK cancer clinical guidelines
British Journal of Cancer (2008)
-
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
British Journal of Cancer (2008)
-
Economics of the clinical management of lung cancer in France: an analysis using a Markov model
British Journal of Cancer (2004)